Cagrilintide vs Semaglutide: side-by-side comparison
AM833 · NNC0174-0833 · Cagri
A long-acting amylin analog developed by Novo Nordisk. Amylin is a satiety hormone released alongside insulin after meals, and it works through a different pathway than GLP-1, so cagrilintide complements GLP-1 agonists rather than duplicating them. It is best known as the amylin half of CagriSema, the fixed-dose once-weekly combination of cagrilintide 2.4mg and semaglutide 2.4mg, which produced 22.7% mean weight loss at 68 weeks in the REDEFINE 1 trial assuming full adherence (the treatment-policy estimate, which counts everyone regardless of adherence, was 20.4%).
Ozempic · Wegovy · Rybelsus
A GLP-1 receptor agonist used for weight loss, appetite suppression, and type 2 diabetes management. Originally developed and approved as Ozempic for diabetes, the same drug is now FDA-approved as Wegovy for chronic weight management (injectable and, since December 2025, an oral tablet) and as Rybelsus for oral diabetes treatment. Also carries FDA approvals for reducing major cardiovascular events (SELECT trial) and slowing chronic kidney disease progression in type 2 diabetics (FLOW trial).
3 / 10 natty scale / 3
Same lane
Both sit in the same class and are run for cutting. This is a like-for-like comparison: read the gaps as real trade-offs.
The tape
Core ratings
The same three rulers every entry on the site is scored with, read head to head.
Natty scale
1 natural · 10 heavy
Effectiveness
Documented effect · of 5Δ0.5
Side-effect severity
Documented burden · of 5Δ0.5
Cost side
Body-load fingerprint
Where each one actually lands its strain, on the calculator's thirteen channels. Tap a row for what it means and which labs track it.
Organ strain
Systemic
Injection & site care
Bars show strain at each one's typical protocol, not your dose. ≈ marks values inferred from side-effect data or category rather than hand-graded. For your numbers, run the calculator.
Logistics
The vitals
Benefit side
What each is for
Shared goals carry both dots; a goal with one dot belongs to that side alone.
Run for
Documented upside
- Distinct amylin mechanism that stacks with GLP-1 agonists
- Strong combination results as CagriSema (~22.7% mean weight loss at 68 weeks)
- Once-weekly subcutaneous dosing
- Generally well tolerated at lower doses
- Improves multiple metabolic markers alongside weight loss
Run for
Documented upside
- Significant appetite reduction
- Substantial weight loss (~15% at 68 weeks in STEP 1)
- Improved blood sugar control
- Once-weekly dosing (injectable forms)
- FDA-approved with extensive safety data
The downsides
Side effects, aligned
Each entry's documented side effects, sorted onto the same body systems so the gaps and the overlaps are visible. Tap any effect for the detail.
None documented
The exit
Hormonal fallout & recovery
What each does to your own hormone axis while on, and what leaving it costs.
Cagrilintide
Not hormonal (in the anabolic sense). Does not affect the HPTA. No PCT required. Weight regain is common after stopping unless habits are maintained.
Semaglutide
Not hormonal. No PCT required.
Read-out
How they separate
- 01
Enhancement
They land at almost the same point on the natty scale (3/10 vs 3/10): a similar distance beyond natural.
- 02
Side-effect bill
Semaglutide's documented side-effect severity is heavier (3/5 vs 2.5/5). The body-load fingerprint above shows where that weight actually lands.
- 03
Body load
The widest gap at typical protocols is heart structure (Semaglutide 2.8/10 vs 0/10).
- 04
Coming off
Neither requires PCT: both leave the natural testosterone axis running.
Generated from each entry's data file. Descriptive, not a recommendation; nothing here is medical advice.